Post on 04-Jan-2016
Pharmacy ServicesPharmacy Services
Dexmedetomidine (Precedex®)
Haley Gill, BSPVCH-PHC Pharmacy Resident 2009-2010
Pharmacy ServicesPharmacy Services
Outline
• Current indications
• Differences & possible advantages over current sedation agents
• Pharmacology
• Dosing
• Cost
• Review of Literature
Pharmacy ServicesPharmacy Services
Health Canada
• Precedex®
• NOC issued December 2009
• Dexmedetomidine (DXM) 100mcg/ml solution
• Continuous IV infusion
Pharmacy ServicesPharmacy Services
Health Canada - Approved Indications
• ICU Sedation:– post-surgical mechanically ventilated patients – Infusion must NOT exceed 24 hours– Not necessary to D/C prior to extubation– ↓ dose by 50% after extubation
• Conscious Sedation (non-intubated patients):– Monitored Anesthesia Care– Awake Fiberoptic Intubation
Pharmacy ServicesPharmacy Services
DXM vs. Other ICU Sedation Agents
• Minimal respiratory depression
• Thought to induce less delirium – does not bind to GABA receptors
• Analgesic sparing
• Does not provide adequate & reliable amnesia
Pharmacy ServicesPharmacy Services
Pharmacology
• MOA – highly selective α2-adrenoreceptor agonist
– Similar to clonidine but 8 X more selective for α2
α2-adrenoreceptors Pancreatic β-cells ↓ insulin secretion
Platelets Aggregation
Nerve Terminals ↓ release of NE
Vascular Smooth muscle Contraction
Pharmacy ServicesPharmacy Services
Pharmacology
Pharmacy ServicesPharmacy Services
Pharmacology
Onset of Action 5-10 min
Peak effect: 15-30 min
Duration of Action 60-120 min
Metabolism Hepatic via N-glucuronidation, N-methylation, & CYP2A6
Elimination t1/2 ~ 6 min
Terminal: ~2 hrs
Excretion Urine 95%
Feces 4%
Pharmacy ServicesPharmacy Services
Drug Interactions
Enzyme Action Drugs
CYP 2A6 substrate amiodarone isoniazid
ketoconazole
CYP 1A2, 2C9, 3A4
weak inhibitor warfarin
Simvastatin
CYP 2D6 strong inhibitor codeine
**theoretical interactions – likely of little clinical significance**
Pharmacy ServicesPharmacy Services
Drug Interactions
• Beta-blockers: rebound hypertensive effect when the α2-agonist is abruptly withdrawn
• Mirtazapine: α2-antagonist (opposing effects)
Pharmacy ServicesPharmacy Services
Dosing• ICU sedation
– Load: 1 mcg/kg IV over 10 minutes– Maintenance: 0.2-0.7 mcg/kg/hr IV (0.2-1.4 mcg/kg/hr
reported in RCT’s) – titration no more frequently than every 30 minutes may
↓ the incidence of hypotension
• Procedural sedation– Load: 0.5 – 1 mcg/kg over 10 minutes – Maintenance: 0.6 mcg/kg/hr (usual range: 0.2-1
mcg/kg/hr)
Pharmacy ServicesPharmacy Services
Dosing
• No specific recommendations for renal or hepatic dysfunction
Pharmacy ServicesPharmacy Services
Adverse Effects
• Hypotension (24-54%)
• Bradycardia (5-14%)• Respiratory
depression (37%; placebo 32%)
• Atrial fibrillation (4-5%)• Hypovolemia (3%)
• ↓ urine output• Pleural effusion • Hypocalcemia (1%)• Nausea (3-9%)• Xerostomia (3-4%)• Hyperglycemia
Pharmacy ServicesPharmacy Services
Cost
Drug Unit Cost Cost/day for 70 kg ptDXM 100mcg/ml 2 ml vial = $63 $105.84 - $370.44
(0.2 – 0.7mcg/kg/hr)
Propofol 10mg/ml 100 ml bottle = $8.78 $14.75 – $88.50
(1 – 6mg/kg/hr)
Midazolam 5mg/ml 10 ml vial = $12.25 $29.40 – $58.80
(5 – 10mg/hr)
Pharmacy ServicesPharmacy Services
Effect of Sedation with Dexmedetomidine vs Lorazepam on Acute Brain Dysfunction in Mechanically Ventilated Patients
(MENDS)
Pandharipande P, et al
JAMA 2007;298(22):2644-2653
Pharmacy ServicesPharmacy Services
MENDSObjective To determine whether DXM reduces the duration of delirium and coma in
mechanically ventilated ICU patients while providing adequate sedation as compared to lorazepam
Design P-MC-DB-RCT
Patients n = 106 medical/surgical ICU patients requiring ventilation for >24 hrs
Treatment DXM 0.15 – 1.5 mcg/kg/hr vs lorazepam 1 – 10 mg/hr
Results Delirium-free & coma-free days: DXM 7 vs. loraz 3 (p=0.01)
Prevalence of delirium or coma: DXM 87% vs. loraz 98% (p=0.03)
Time @ target sedation (RASS): 80% vs. 67% (p=0.04)
Ventilator-free days: DXM 22 vs. loraz 18 (p=0.22)
Length of ICU stay (days): DXM 7.5 vs. loraz 9 (p=0.92)
Pharmacy ServicesPharmacy Services
MENDSResults 28-day mortality:
DXM 17% vs. loraz 27% (p=0.18)
Open-label fentanyl use (median dose/day):
DXM 575 mcg vs. loraz 150 mcg (p=0.006)
Bradycardia:
DXM 17% vs. loraz 4% (p=0.03)
Atrial Fibrillation:
DXM 6% vs. loraz 0% (p=0.08)
Conclusion DXM patients had more days alive without coma or delirium
↑ bradycardia with DXM
↑ fentanyl use with DXM
Max duration of DXM = 120 hr
Average dose DXM = 0.74mcg/kg/h
Pharmacy ServicesPharmacy Services
Dexmedetomidine vs Midazolam for Sedation of Critically Ill Patients
(SEDCOM)
Riker R, et al
JAMA 2009;31(5):489-499
Pharmacy ServicesPharmacy Services
SEDCOMObjective To compare efficacy & safety of prolonged sedation with DXM vs.
midazolam for mechanically ventilated patients
Design P-MC-DB-RCT
Patients n = 366 medical/surgical ICU patients with expected ventilation for >24 hrs
Treatment DXM 0.2 – 1.4 mcg/kg/hr vs midazolam 0.02 – 0.1 mg/kg/hr
Results Time @ target sedation (RASS): DXM 77.3% vs. midaz 75.1% (p=0.18)
Duration of study drug treatment (days): DXM 3.5 vs. midaz 4.1 (p=0.01)
Time to extubation (days): DXM 3.7 vs. midaz 5.6 (p=0.01)
Length of ICU stay (days): DXM 5.9 vs. midaz 7.6 (p=0.24)
Delirium: DXM 54% vs. midaz 76.6% (p<0.001)
Pharmacy ServicesPharmacy Services
SEDCOMResults Mean delirium-free days: DXM 2.5 vs. midaz 1.7 (p=0.002)
Open-label midazolam use: DXM 63% vs. midaz 49% (p=0.02)
Fentanyl use: DXM 73.8% vs. midaz 97% (p=0.25)
30 day mortality: DXM 22.5% vs. midaz 25.4% (p=0.6)
Bradycardia: DXM 42.2% vs. midaz 18.9% (p<0.01)
Hyperglycemia: DXM 56.6% vs. midaz 42.6% (p=0.02)
Conclusion No difference in time at target sedation level
↓ time to extubation & ↓ delirium in DXM group
↑ use of midazolam in DXM group
↑ bradycardia & ↑ hyperglycemia in DXM group
Average dose DXM = 0.83 mcg/kg/h
Pharmacy ServicesPharmacy Services
Dexmedetomidine versus propofol/midazolam for long-term sedation
during mechanical ventilation
Ruokonen E, et al
Intensive Care Med 2009;35:282-290
Pharmacy ServicesPharmacy Services
Ruokonen E, et alObjective To compare DXM with standard care (SC) (propofol or midazolam) for
long-term sedation in terms of maintaining target sedation and length of ICU stay
Design P-MC-DB-DD-RCT
Patients n = 85 ICU patients with need for sedation >24 hrs
Treatment DXM ≤1.4 mcg/kg/hr vs propofol or midazolam
Results Time @ target sedation RASS: DXM 64% vs. SC 63% NSS•RASS -4: DXM 42% vs. SC 62%•RASS 0 to -3: DXM 74% vs. 64%
Length of ICU stay (days): DXM 6.6 vs. SC 6.8 [HR 0.766 (p=0.275)]
Duration of ventilation: DXM 77.2 h vs. SC 110.6 h (p=0.109)
Delirium: DXM 43.5% vs. SC 25% (p=0.035)
Pharmacy ServicesPharmacy Services
Ruokonen E, et alResults Serious Adverse Events:
DXM 100% (3 bradycardia, 1 arrest) vs. SC 95.5%
Conclusion DXM comparable to standard sedation when light sedation target
DXM less effective when deep sedation target (RASS -4)
↑ delirium in DXM group but more CAM-ICU assessments in this group
Average DEX dose 0.8mcg/kg/hr
Average duration 40 h (Max duration 14 days)
Pharmacy ServicesPharmacy Services
The effect of dexmedetomidine on agitation during weaning of mechanical ventilation in
critically ill patients
Shehabi Y, et al
Anaesth Intensive Care 2010;38:82-90
Pharmacy ServicesPharmacy Services
Shehabi Y, et alObjective To evaluate the effects of DXM on resolution of agitation during weaning
from mechanical ventilation of critically ill patients who failed conventional therapy
Design P-OL-O
Patients n = 28 ICU patients who developed agitation and/or delirium upon weaning from sedation
Treatment DXM 0.4 mcg/kg/hr for 2 hours, titrated up by 0.2 mcg/kg/hr every 30 min to max dose of 1 mcg/kg/hr
Results • baseline: 77% of patients outside of target MAAS, 23% within target
• 6 h: 93% within target (p<0.001)
•12 h: 87% within target (p<0.001)
73.3% of patients were extubated
Median ventilation time after DXM infusion = 70 h
Conclusion DXM provided resolution of agitation and facilitated extubation
Median infusion time of DXM = 62 h
Pharmacy ServicesPharmacy Services
Summary of Evidence• DXM effective at achieving target sedation• DXM not as effective when deep sedation
required– ↑ use of additional sedation agents in DXM group
• Higher doses of DXM appear safe– No withdrawal/rebound effects seen – loading dose often not used
• Duration > 24 hr appears safe• Appears safe in non-surgical population• May ↓ delirium• Main AE’s: bradycardia, hyperglycemia, AF
Pharmacy ServicesPharmacy Services
Place in Therapy
• Light sedation
• Medical or surgical patients
• Patients who may be at increased risk for delirium
• Patients who are unable to be weaned due to agitation
• Limited data in dialysis patients, severe liver disease, HR <50
Pharmacy ServicesPharmacy Services